Home Newsfeeds Morgan Stanley Upgrades Hello Gr to Overweight, Raises Price Target to $9

Morgan Stanley Upgrades Hello Gr to Overweight, Raises Price Target to $9

Morgan Stanley analyst Alex Poon upgrades Hello Gr (NASDAQ:MOMO) from Equal-Weight to Overweight and raises the price target from $5 to $9.

byBenzinga Newsdesk

December 9, 2022

1 minute read

Morgan Stanley analyst Alex Poon upgrades Hello Gr (NASDAQ:MOMO) from Equal-Weight to Overweight and raises the price target from $5 to $9.

Coca-Cola Analysts Remain Optimistic As Shares Stagnate Despite Impressive First-Quarter Earnings

By Priya Nigam

April 25, 11:25 AM

Shares of Coca-Cola Co (NYSE: KO) Tuesday continued to fizzle out despite the company reporting upbeat first-quarter results.

Tharimmune Announces Results In Phase 1 Clinical Trial Of TH104, Compared Oral Transmucosal Delivery Of TH104 To Injectable Reference Approved Drug Completed

By Benzinga Newsdesk

February 20, 9:08 AM

Positive safety/tolerability profile achieved with TH104 showing self-resolving, mild side effect profile aligned with previous studiesPhase 1 clinical trial compared oral transmucosal delivery of TH104 to injectable

THAR

Medigus Announces Polyrizon Signs Binding Collaboration Agreement With NurExone Biologic For Intranasal Administration Of Therapy For Spinal Cord Injuries, Polyrizon Is Entitled For Up to $3.35M Plus Future Royalties; Medigus Owns 37.03% Of Polyrizon

By Bill Haddad

July 18, 8:07 AM

Medigus Ltd. (NASDAQ:MDGS), a technology company engaged in advanced medical solutions, innovative internet technologies, and electric vehicle and charging solutions, announced today that Polyrizon Ltd.

MDGS

Alabama’s Third Attempt To Set Up Its Medical Cannabis Industry: 20 Licenses Granted For Now

By Jelena Martinovic

December 4, 11:11 AM

Alabama's cannabis regulator granted 20 licenses recently for the production and distribution of medical marijuana, reported the Alabama Reflector.

VRNOF

Morgan Stanley Upgrades Hello Gr to Overweight, Raises Price Target to $9

Related Posts

Coca-Cola Analysts Remain Optimistic As Shares Stagnate Despite Impressive First-Quarter Earnings

Tharimmune Announces Results In Phase 1 Clinical Trial Of TH104, Compared Oral Transmucosal Delivery Of TH104 To Injectable Reference Approved Drug Completed

Medigus Announces Polyrizon Signs Binding Collaboration Agreement With NurExone Biologic For Intranasal Administration Of Therapy For Spinal Cord Injuries, Polyrizon Is Entitled For Up to $3.35M Plus Future Royalties; Medigus Owns 37.03% Of Polyrizon

Alabama’s Third Attempt To Set Up Its Medical Cannabis Industry: 20 Licenses Granted For Now